The post Here’s how OKB’s latest 26% rally could trap late buyers near the price top appeared on BitcoinEthereumNews.com. OKB, the native token of the OKX exchangeThe post Here’s how OKB’s latest 26% rally could trap late buyers near the price top appeared on BitcoinEthereumNews.com. OKB, the native token of the OKX exchange

Here’s how OKB’s latest 26% rally could trap late buyers near the price top

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

OKB, the native token of the OKX exchange, recorded a strong rally recently, one that placed it among the top gainers of the day.

Its 26% surge followed a six-week decline that wiped roughly 39% from its value after its peak during the week beginning 12 January. A recent investment announcement has now improved sentiment around the altcoin, raising expectations of a potential rebound on the charts.

OKX receives $25 billion valuation

OKB’s rally followed a major investment announcement from Intercontinental Exchange, the parent company of New York Stock Exchange. The deal places OKX at a valuation of $25 billion.

Thursday’s announcement triggered renewed interest in OKB, the exchange’s native token. The development also strengthens the exchange’s fundamental outlook, as it is evidence of one of the world’s largest financial infrastructure firm’s backing.

According to the company, the investment is also indicative of confidence that digital assets— including cryptocurrencies — will play a central role in the global financial system.

The firm added that its focus will center on “durable infrastructure for the global financial system.” It specifically highlighted “tokenized securities and digital representations of traditional assets” as an area with strong future potential. At the time of writing, the total cryptocurrency market capitalization stood at about $2.41 trillion, while tokenized assets were valued at roughly $13.4 billion.

OKX is not alone in exploring the intersection between traditional finance and digital assets though. Kraken and Coinbase have also announced similar initiatives aimed at expanding their presence across both markets.

Does the news justify buying OKB?

While investment does improve the long-term outlook for OKX, it does not necessarily mean that OKB is an attractive buy at its press time price level.

Data from the Relative Strength Index (RSI), which measures whether an asset is overbought or oversold, suggested that traders may now be purchasing OKB at elevated levels.

The RSI has already moved above the 70-threshold that typically signals overbought conditions. From a technical standpoint, this often means that an asset could face a correction as the price moves closer to its fair market value.

Source: TradingView

However, the indicator does not specify when such a move might occur. This means OKB could still extend its rally even while trading in overbought territory.

Another technical metric, the Aroon Indicator, also pointed to growing downside pressure. At press time, the Aroon Up line (yellow) was slightly above the Aroon Down line (blue) – A sign that bearish momentum has been building gradually.

Together, these signals suggested that traders should approach the market carefully. Especially since long-term price direction remains uncertain.

Spot investors increase market exposure

Despite the technical warnings though, market reaction to the investment news has been positive.

The rally attracted fresh activity from spot investors, who purchased approximately $1.88 million worth of OKB during the period following the announcement.

Weekly spot netflows also reached their highest level in four weeks, rising to $2.87 million.

Source: CoinGlass

Sustained buying at this pace could provide short-term support for the altcoin’s price. If demand remains strong, it may limit the depth of a potential pullback should the anticipated correction emerge.


Final Summary

  • A $25 billion valuation for OKX sparked a wave of buying that pushed OKB’s value sharply higher.
  • Technical indicators suggested the asset may now be overvalued, requiring caution from traders.
Previous: Crypto market slides as Bitcoin falls to $68K and Ethereum drops below $2K
Next: ‘Unlock for tokenization? ’- OCC clarifies capital rules for tokenized securities 

Source: https://ambcrypto.com/heres-how-okbs-latest-26-rally-could-trap-late-buyers-near-the-price-top/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09